4 Results for "

multidrug-resistant hepatocellular carcinoma cells

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "multidrug-resistant hepatocellular carcinoma cells" in MCE Product Catalog:

4
Arenobufagin
Arenobufagin
0 Images
4 Cited Publications
Cat. No.: HY-N0876
CAS No.: 464-74-4
Category:  

Animals Disease Research Fields Cancer Steroids

Target:  

Apoptosis Autophagy PI3K Akt mTOR PARP Caspase Atg8/LC3

Arenobufagin is a natural bufadienolide that can be extracted from toad venom. Arenobufagin can induce apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Arenobufagin has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells. Arenobufagin can inhibit VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway .
loading...
    loading...
View All Sizes
23-Hydroxybetulinic acid
23-Hydroxybetulinic acid
0 Images
Cat. No.: HY-N0566
CAS No.: 85999-40-2
Synonyms: Anemosapogenin
Category:  

Triterpenes Terpenoids Plants Other Families Extract Disease Research Fields Cancer

Target:  

Apoptosis Autophagy Bcl-2 Family Caspase Survivin p38 MAPK MMP

23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer .
loading...
    loading...
View All Sizes
Arenobufagin (Standard)
Arenobufagin (Standard)
0 Images
Cat. No.: HY-N0876R
CAS No.: 464-74-4
Category:  

Animals Steroids

Target:  

Reference Standards Apoptosis Autophagy PI3K Akt mTOR PARP Caspase Atg8/LC3

Arenobufagin is a natural bufadienolide that can be extracted from toad venom. Arenobufagin can induce apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Arenobufagin has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells. Arenobufagin can inhibit VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway .
loading...
    loading...
View All Sizes
23-Hydroxybetulinic acid (Standard)
23-Hydroxybetulinic acid (Standard)
0 Images
Cat. No.: HY-N0566R
CAS No.: 85999-40-2
Synonyms: Anemosapogenin (Standard)
Category:  

Triterpenes Terpenoids Plants Other Families Extract

Target:  

Reference Standards Apoptosis Autophagy Bcl-2 Family Caspase Survivin p38 MAPK MMP

23-Hydroxybetulinic acid (Standard) is the analytical standard of 23-Hydroxybetulinic acid (HY-N0566). This product is intended for research and analytical applications. 23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer.
loading...
    loading...
View All Sizes
Assay Types